BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20141719)

  • 1. Treating dyslipidemia in the high-risk patient.
    Jones PH
    J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of dyslipidemia in clinical practice].
    Paragh G; Harangi M
    Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low HDL-C: a secondary target of dyslipidemia therapy.
    Rosenson RS
    Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy vs combination therapy for dyslipidemia in the elderly.
    Shepherd J
    Am J Geriatr Cardiol; 2008; 17(2):108-13. PubMed ID: 18326949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):562-9. PubMed ID: 18447654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin's role in the statin era.
    Brooks EL; Kuvin JT; Karas RH
    Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
    Miller M; Ginsberg HN; Schaefer EJ
    Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.